American Century Companies Inc. Sells 52,349 Shares of Neurocrine Biosciences, Inc. $NBIX

American Century Companies Inc. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 27.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 138,913 shares of the company’s stock after selling 52,349 shares during the quarter. American Century Companies Inc. owned 0.14% of Neurocrine Biosciences worth $19,501,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of NBIX. Geneos Wealth Management Inc. raised its position in shares of Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. Golden State Wealth Management LLC increased its stake in Neurocrine Biosciences by 120.5% during the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after acquiring an additional 100 shares during the last quarter. Eastern Bank bought a new stake in Neurocrine Biosciences during the third quarter worth approximately $27,000. Quent Capital LLC purchased a new stake in Neurocrine Biosciences during the third quarter valued at approximately $32,000. Finally, MAI Capital Management lifted its stake in shares of Neurocrine Biosciences by 101.2% in the 2nd quarter. MAI Capital Management now owns 328 shares of the company’s stock valued at $41,000 after purchasing an additional 165 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In other news, Director Leslie V. Norwalk sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $152.23, for a total transaction of $761,150.00. Following the transaction, the director directly owned 7,429 shares of the company’s stock, valued at approximately $1,130,916.67. This trade represents a 40.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kyle Gano sold 36,400 shares of the stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the transaction, the chief executive officer directly owned 140,407 shares in the company, valued at approximately $18,632,008.90. This trade represents a 20.59% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 42,590 shares of company stock worth $5,775,987 over the last 90 days. Insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Citigroup boosted their target price on Neurocrine Biosciences from $203.00 to $204.00 and gave the company a “buy” rating in a research report on Thursday, February 12th. UBS Group dropped their price objective on shares of Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. JPMorgan Chase & Co. cut their price objective on shares of Neurocrine Biosciences from $177.00 to $176.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. Zacks Research downgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong sell” rating in a research note on Tuesday, February 17th. Finally, Royal Bank Of Canada lowered their target price on shares of Neurocrine Biosciences from $180.00 to $177.00 and set an “outperform” rating for the company in a report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $175.05.

Neurocrine Biosciences Stock Up 1.4%

Shares of Neurocrine Biosciences stock opened at $129.93 on Tuesday. Neurocrine Biosciences, Inc. has a 52 week low of $84.23 and a 52 week high of $160.18. The company has a market capitalization of $13.04 billion, a PE ratio of 27.88, a price-to-earnings-growth ratio of 0.67 and a beta of 0.32. The stock’s fifty day moving average is $134.04 and its two-hundred day moving average is $140.47.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 EPS for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The company had revenue of $805.50 million during the quarter, compared to the consensus estimate of $804.21 million. During the same quarter in the previous year, the company posted $1.69 earnings per share. The company’s revenue for the quarter was up 28.3% on a year-over-year basis. As a group, research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.